AMD shares rise ahead of strong earnings forecast, outpacing sector and S&P 500
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Eli Lilly posts blowout Q3 results, raises 2025 outlook, and sees strong demand for its GLP-1 medicines.
AMD shares rise ahead of strong earnings forecast, outpacing sector and S&P 500
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Eli Lilly posts blowout Q3 results, raises 2025 outlook, and sees strong demand for its GLP-1 medicines.
